Regenerative Medical Technology (RMTG) Net Cash Flow Growth (3y) (2021 - 2026)
Regenerative Medical Technology (RMTG) Net Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -35.85% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 106.37% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 67.39% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -70.95% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 52.78% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.55% |
| 10 | Regenerative Medical Technology | 1.58 Mn | 515,228.12 | 1.77 Mn | 142.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 142.35% |
| Dec 31, 2025 | -22.54% |
| Sep 30, 2025 | -40.39% |
| Jun 30, 2025 | -13.62% |
| Mar 31, 2025 | 28.27% |
| Dec 31, 2024 | 26.88% |
| Sep 30, 2024 | -2.35% |
| Jun 30, 2024 | -84.41% |
| Mar 31, 2024 | -59.69% |
| Dec 31, 2023 | -230.84% |
| Sep 30, 2023 | -54.61% |
| Jun 30, 2023 | -116.76% |
| Mar 31, 2023 | 10.85% |
| Dec 31, 2022 | -94.25% |
| Sep 30, 2022 | -56.88% |
| Jun 30, 2022 | -130.87% |
| Mar 31, 2022 | -157.66% |
| Dec 31, 2021 | -2,354.97% |
| Sep 30, 2021 | 202.12% |
| Jun 30, 2021 | 642.83% |